Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-01-13
2000-01-25
Dentz, Bernard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514394, 514562, 514564, 514565, 546122, 5483044, 560 13, 560 35, 560 41, 562427, 562444, 562450, A61K 31435, C07D47104
Patent
active
060179252
ABSTRACT:
This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. The vitronectin receptor antagonist compounds of the present invention are .alpha.v.beta.3 antagonists, .alpha.v.beta.5 antagonists or dual .alpha.v.beta.3/.alpha.v.beta.5 antagonists useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.
REFERENCES:
patent: 5260277 (1993-11-01), McKenzie
patent: 5455243 (1995-10-01), Duggan et al.
patent: 5534524 (1996-07-01), Bonewald et al.
patent: 5563158 (1996-10-01), DeGrado et al.
patent: 5668159 (1997-09-01), Jin et al.
patent: 5741796 (1998-04-01), Hartman et al.
patent: 5786373 (1998-07-01), Hartman et al.
Dentz Bernard
Durette Philippe L.
Merck & Co. , Inc.
Sabatelli Anthony D.
Winokur Melvin
LandOfFree
Integrin antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2316145